Browse by author
Lookup NU author(s): Huw ThomasORCiD, Gordon Taylor, Professor Herbie Newell, Professor Alan Boddy
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The antitumour effect of thymidylate synthase inhibitors such as raltitrexed (RTX) may be reversed by salvage of thymidine (Thd). Since thymidine phosphorylase (TP) depletes Thd, the potential for tumour-selective depletion of Thd using antibody-mediated delivery of TP to tumours was investigated. In vitro studies demonstrated that 25 × 10-3 units/ml TP depleted extracellular Thd (3 μM) and restored sensitivity to the growth inhibitory effects of RTX in Lovo and HT29 cell lines. Thymidine concentrations in xenograft tumours were inversely proportional to the activity of TP in the tumour, and the presence of a subcutaneous Lovo xenograft reduced plasma Thd concentrations from 0.92 ± 0.07 to 0.37 ± 0.04 μM. Intravenous administration of native TP enzyme depleted plasma Thd to 5 nM, but following rapid elimination of TP, plasma Thd returned to pretreatment values. There was no effect on tumour TP or Thd. Conjugation of TP to the A5B7 F(ab)2 antibody fragment, which targets carcinoembryonic antigen (CEA) expressed on colorectal cell-lines such as Lovo, did result in selective accumulation of TP in the tumour. However, there was no tumour-selective depletion of Thd and there did not appear to be any potential benefit of combining antibody-targeted TP with RTX. © 2006 Springer-Verlag.
Author(s): Graham-Cole C, Thomas HD, Taylor GA, Newell DR, Melton R, Hesp R, Boddy AV
Publication type: Article
Publication status: Published
Journal: Cancer Chemotherapy and Pharmacology
Year: 2007
Volume: 59
Issue: 2
Pages: 197-206
Print publication date: 01/02/2007
ISSN (print): 0344-5704
ISSN (electronic): 1432-0843
URL: http://dx.doi.org/10.1007/s00280-006-0258-x
DOI: 10.1007/s00280-006-0258-x
PubMed id: 16721548
Altmetrics provided by Altmetric
